Brooks, Dominique L.
Carrasco, Manuel J. http://orcid.org/0000-0002-8253-2937
Qu, Ping
Peranteau, William H.
Ahrens-Nicklas, Rebecca C.
Musunuru, Kiran http://orcid.org/0000-0003-3298-0368
Alameh, Mohamad-Gabriel http://orcid.org/0000-0002-5672-6930
Wang, Xiao http://orcid.org/0000-0001-7502-8292
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01-HL148769, U19-NS132301)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 25 February 2023
Accepted: 6 June 2023
First Online: 10 June 2023
Competing interests
: K.M. is an advisor to and holds equity in Verve Therapeutics and Variant Bio and is an advisor to LEXEO Therapeutics. M.-G.A. is a co-founder of and an advisor to AexeRNA Therapeutics. The University of Pennsylvania has filed a patent application related to the use of base editing for the treatment of phenylketonuria (inventors D.L.B., K.M., and X.W.). The remaining authors declare no competing interests.